Clinical trial demonstrates significant symptom relief from transurethral ethanol chemo-ablation in men with prostatic obstruction, indicating a promising minimally invasive treatment.
PURPOSE: We confirmed clinically whether chemo-ablation of the prostate with absolute ethanol may be an innovative transurethral approach for the relief of obstructive benign prostatic hyperplasia. METHODS: Using the InjecTx endoscopic device (Injectx Inc., San Jose, California) an initial cohort of 15 patients, including 13 who have now been followed more than 1 year, underwent elective transurethral chemo-ablation of the prostate. RESULTS: Preoperative and postoperative comparisons of the American Urological Association symptom score, maximum urine flow rate and prostatic volume reveal significant improvement with minimal discomfort and no major complication. CONCLUSIONS: The InjecTx technique proved encouragingly successful in this initial small-scale clinical trial.
No takes yet. Share an insight, caveat, or question.
DiTrolio et al. (2002) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: